Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles
Exploitation of biological properties unique to cancer cells may provide a novel approach to overcome difficult challenges to the treatment of advanced melanoma. In order to develop melanoma-targeted chemothermoimmunotherapy, a melanogenesis substrate, N-propionyl-4-S-cysteaminylphenol (NPrCAP), sul...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Journal of Skin Cancer |
| Online Access: | http://dx.doi.org/10.1155/2013/742925 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566742643113984 |
|---|---|
| author | Kowichi Jimbow Yasue Ishii-Osai Shosuke Ito Yasuaki Tamura Akira Ito Akihiro Yoneta Takafumi Kamiya Toshiharu Yamashita Hiroyuki Honda Kazumasa Wakamatsu Katsutoshi Murase Satoshi Nohara Eiichi Nakayama Takeo Hasegawa Itsuo Yamamoto Takeshi Kobayashi |
| author_facet | Kowichi Jimbow Yasue Ishii-Osai Shosuke Ito Yasuaki Tamura Akira Ito Akihiro Yoneta Takafumi Kamiya Toshiharu Yamashita Hiroyuki Honda Kazumasa Wakamatsu Katsutoshi Murase Satoshi Nohara Eiichi Nakayama Takeo Hasegawa Itsuo Yamamoto Takeshi Kobayashi |
| author_sort | Kowichi Jimbow |
| collection | DOAJ |
| description | Exploitation of biological properties unique to cancer cells may provide a novel approach to overcome difficult challenges to the treatment of advanced melanoma. In order to develop melanoma-targeted chemothermoimmunotherapy, a melanogenesis substrate, N-propionyl-4-S-cysteaminylphenol (NPrCAP), sulfur-amine analogue of tyrosine, was conjugated with magnetite nanoparticles. NPrCAP was exploited from melanogenesis substrates, which are expected to be selectively incorporated into melanoma cells and produce highly reactive free radicals through reacting with tyrosinase, resulting in chemotherapeutic and immunotherapeutic effects by oxidative stress and apoptotic cell death. Magnetite nanoparticles were conjugated with NPrCAP to introduce thermotherapeutic and immunotherapeutic effects through nonapoptotic cell death and generation of heat shock protein (HSP) upon exposure to alternating magnetic field (AMF). During these therapeutic processes, NPrCAP was also expected to provide melanoma-targeted drug delivery system. |
| format | Article |
| id | doaj-art-289fe2168cd146a6a7a5e890b909a8a9 |
| institution | Kabale University |
| issn | 2090-2905 2090-2913 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Skin Cancer |
| spelling | doaj-art-289fe2168cd146a6a7a5e890b909a8a92025-02-03T01:03:21ZengWileyJournal of Skin Cancer2090-29052090-29132013-01-01201310.1155/2013/742925742925Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite NanoparticlesKowichi Jimbow0Yasue Ishii-Osai1Shosuke Ito2Yasuaki Tamura3Akira Ito4Akihiro Yoneta5Takafumi Kamiya6Toshiharu Yamashita7Hiroyuki Honda8Kazumasa Wakamatsu9Katsutoshi Murase10Satoshi Nohara11Eiichi Nakayama12Takeo Hasegawa13Itsuo Yamamoto14Takeshi Kobayashi15Institute of Dermatology & Cutaneous Sciences, 1-27 Odori West 17, Chuo-ku, Sapporo 060-0042, JapanDepartment of Dermatology, School of Medicine, Sapporo Medical University, South 1 West 16, Chuo-ku, Sapporo 060-8556, JapanDepartment of Chemistry, School of Health Sciences, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, JapanDepartment of Pathology 1, School of Medicine, Sapporo Medical University, South 1 West 16, Chuo-ku, Sapporo 060-8556, JapanDepartment of Chemical Engineering, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, JapanDepartment of Dermatology, School of Medicine, Sapporo Medical University, South 1 West 16, Chuo-ku, Sapporo 060-8556, JapanDepartment of Dermatology, School of Medicine, Sapporo Medical University, South 1 West 16, Chuo-ku, Sapporo 060-8556, JapanDepartment of Dermatology, School of Medicine, Sapporo Medical University, South 1 West 16, Chuo-ku, Sapporo 060-8556, JapanDepartment of Biotechnology, School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, JapanDepartment of Chemistry, School of Health Sciences, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, JapanMeito Sangyo Co., Ltd., 25-5 Kaechi, Nishibiwajima-cho, Kiyosu, Aichi 452-0067, JapanMeito Sangyo Co., Ltd., 25-5 Kaechi, Nishibiwajima-cho, Kiyosu, Aichi 452-0067, JapanFaculty of Health and Welfare, Kawasaki University of Medical Welfare, 288 Matsushimai, Kurashiki, Okayama 701-0193, JapanDepartment of Hyperthermia Medical Research Laboratory, Louis Pasteur Center for Medical Research, 103-5, Tanakamonzen-cho, Sakyo-ku, Kyoto 606-8225, JapanYamamoto Vinita Co., Ltd., 3-12 ueshio 6, Tennoji-ku, Osaka 543-0002, JapanDepartment of Biological Chemistry, College of Bioscience and Biotechnology, Chubu University, 1200 Matsumoto-cho, Kasugai, Aichi 487-8501, JapanExploitation of biological properties unique to cancer cells may provide a novel approach to overcome difficult challenges to the treatment of advanced melanoma. In order to develop melanoma-targeted chemothermoimmunotherapy, a melanogenesis substrate, N-propionyl-4-S-cysteaminylphenol (NPrCAP), sulfur-amine analogue of tyrosine, was conjugated with magnetite nanoparticles. NPrCAP was exploited from melanogenesis substrates, which are expected to be selectively incorporated into melanoma cells and produce highly reactive free radicals through reacting with tyrosinase, resulting in chemotherapeutic and immunotherapeutic effects by oxidative stress and apoptotic cell death. Magnetite nanoparticles were conjugated with NPrCAP to introduce thermotherapeutic and immunotherapeutic effects through nonapoptotic cell death and generation of heat shock protein (HSP) upon exposure to alternating magnetic field (AMF). During these therapeutic processes, NPrCAP was also expected to provide melanoma-targeted drug delivery system.http://dx.doi.org/10.1155/2013/742925 |
| spellingShingle | Kowichi Jimbow Yasue Ishii-Osai Shosuke Ito Yasuaki Tamura Akira Ito Akihiro Yoneta Takafumi Kamiya Toshiharu Yamashita Hiroyuki Honda Kazumasa Wakamatsu Katsutoshi Murase Satoshi Nohara Eiichi Nakayama Takeo Hasegawa Itsuo Yamamoto Takeshi Kobayashi Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles Journal of Skin Cancer |
| title | Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles |
| title_full | Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles |
| title_fullStr | Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles |
| title_full_unstemmed | Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles |
| title_short | Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles |
| title_sort | melanoma targeted chemothermotherapy and in situ peptide immunotherapy through hsp production by using melanogenesis substrate nprcap and magnetite nanoparticles |
| url | http://dx.doi.org/10.1155/2013/742925 |
| work_keys_str_mv | AT kowichijimbow melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT yasueishiiosai melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT shosukeito melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT yasuakitamura melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT akiraito melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT akihiroyoneta melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT takafumikamiya melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT toshiharuyamashita melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT hiroyukihonda melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT kazumasawakamatsu melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT katsutoshimurase melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT satoshinohara melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT eiichinakayama melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT takeohasegawa melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT itsuoyamamoto melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles AT takeshikobayashi melanomatargetedchemothermotherapyandinsitupeptideimmunotherapythroughhspproductionbyusingmelanogenesissubstratenprcapandmagnetitenanoparticles |